SCHEMBL23960936

SCHEMBL23960936

Cc1ccc(-c2ccc(NC(=O)OC(C)(C)C)c(NC(=O)c3ccc(N4CCN(C(=O)OC(C)(C)C)CC4)cn3)c2)cc1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
MAPT P10636 2/20 0.54
TSHR P16473 1/20 0.54
WNT3A P56704 3/20 0.52
HDAC3 O15379 5/20 0.49
HDAC2 Q92769 4/20 0.49
CYP2C19 P33261 2/20 0.48
KCNH2 Q12809 2/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2C18 P33260 1/20 0.48
TP53 P04637 2/20 0.44
GPR119 Q8TDV5 1/20 0.44
BACE1 P56817 2/20 0.43
ALK Q9UM73 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20181718 0.93 HDAC3 (0.57) MEN1KMT2ASMN1; SMN2MAPTTSHR
SCHEMBL20181660 0.92 KCNH2 (0.58) MEN1KMT2ASMN1; SMN2MAPTTSHR
SCHEMBL20163065 0.92 HDAC2 (0.54) MEN1KMT2ASMN1; SMN2MAPTTSHR
SCHEMBL20163064 0.90 MEN1 (0.51) MEN1KMT2ASMN1; SMN2MAPTTSHR
SCHEMBL20163050 0.88 HDAC3 (0.60) MEN1KMT2ASMN1; SMN2MAPTTSHR
SCHEMBL23960906 0.88 SMN1; SMN2 (0.51) MEN1KMT2ASMN1; SMN2MAPTTSHR
SCHEMBL21275921 0.87 HDAC3 (0.62) MEN1KMT2ASMN1; SMN2MAPTTSHR
SCHEMBL20181517 0.87 HDAC2 (0.55) MEN1KMT2ASMN1; SMN2MAPTTSHR
SCHEMBL20163093 0.86 HDAC3 (0.60) MEN1KMT2ASMN1; SMN2MAPTTSHR
SCHEMBL20163045 0.84 HDAC3 (0.69) HDAC3HDAC2CYP2C19KCNH2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210332036-A1 PYRIMIDINE AND PYRAZINE HDAC1,2 INHIBITORS REGENACY PHARMACEUTICALS LLC (US) 2021-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210332036-A1 PYRIMIDINE AND PYRAZINE HDAC1,2 INHIBITORS HDAC1, HDAC2, HDAC11 MEN1 4613/4885KMT2A 258/4885SMN1; SMN2 1802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.